IMP3 predicts aggressive superficial urothelial carcinoma of the bladder

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1701-1706

  Sitnikova, Lioudmila ^a   Mendese, Gary ^a   Liu, Qin ^a   Woda, Bruce A ^a   Lu, Di ^a   Dresser, Karen ^a   Mohanty, Sambit ^a   Rock, Kenneth L ^a   Jiang, Zhong ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Three Biotech ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMP3 PROTEIN; ONCOFETAL ANTIGEN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROGNOSIS; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 41549104697     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2039     Document Type: Article

References (22)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
3. Sengupta S, Blute ML. The management of superficial transitional cell carcinoma of the bladder. Urology 2006;67:48-54.
4. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology 2003;62:1083-8.
5. Holzbeierlein JM, Smith JA, Jr. Surgical management of noninvasive bladder cancer (stages Ta/T1/CIS). Urol Clin North Am 2000;27:15-24.
6. Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994;151:31-5.
7. Freeman JA, Esrig D, Stein JP, et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995;76:833-9.
8. Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2) [see comment]. J Urol 1990;144:641-5.
9. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006;7:556-64.
10. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999;19:1262-70.
11. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999;88:95-9.
12. Monk D, Bentley L, Beechey C, et al. Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J Med Genet 2002;39:575-81.
13. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14:2729-33.
14. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003;88:887-94.
15. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005;29:188-95.
16. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding Protein IMP-3 Is a Translational Activator of Insulin-like Growth Factor II Leader-3 mRNA during Proliferation of Human K562 Leukemia Cells. J Biol Chem 2005;280:18517-24.
17. Vikesaa J, Hansen TV, Jonson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006;25:1456-68.
18. Habuchi T, Marberger M, Droller MJ, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005;66:64-74.
19. Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6:678-86.
20. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296-9.
21. Stockle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R. Radical cystectomy - often too late? Eur Urol 1987;13:361-7.
22. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 2002;287:49-54.